Radiofrequency Ablation as a Treatment Strategy for Liver Metastases from Breast Cancer

ABSTRACT

The American Cancer Society estimates that in 2007, 178,000 women in the United States will be diagnosed, and that 40,000 women will die from breast cancer. Metastatic breast cancer is a systemic disease, uncommonly involving an isolated organ. Liver metastases from breast cancer occur in ~50% of the patients who develop breast cancer metastases and are associated with a poor outcome. Hepatic metastasectomy as an adjuvant treatment even in patients with stable extrahepatic disease has been shown to impart a significant survival advantage over chemotherapy alone. In the treatment of hepatocellular carcinoma (HCC) and colorectal liver metastases (CRLM), radiofrequency ablation (RFA) has been shown to be a safe, minimally invasive treatment option with low morbidity and short hospital stay that is more readily repeatable than resection. The data supporting RFA of breast cancer liver metastases (BCLM) is currently limited to small, retrospective series that, like hepatic resection, have demonstrated adjuvant RFA improves survival compared with chemotherapy alone. This review will examine the rationale, indications, supportive data, and complications of RFA in the treatment of BCLM.

Ablation - radiofrequency ablation - breast cancer - liver metastases

REFERENCES

• 1 American Cancer Society .Breast Cancer Facts & Figures 2007–2008. Atlanta, GA; American Cancer Society, Inc. 2008
• 2 Surveillance E, Results E. (SEER) Program Registries, Division of Cancer Control and Population Science. Bethesda, MD; National Cancer Institute 2007
• 3 Atalay G, Biganzoli L, Renard F et al.. EORTC Breast Cancer and Early Clinical Studies Groups. Clinical outcome of breast cancer patients with liver metastases alone in the anthracycline-taxane era: a retrospective analysis of two prospective, randomised metastatic breast cancer trials.  Eur J Cancer. 2003;  39(17) 2439-2449
• 4 Jardines L, Callans L S, Torosian M G. Recurrent breast cancer: Presentation, diagnosis and treatment.  Semin Oncol. 1993;  20 538-547
• 5 Elias D, Maisonnette F, Druet-Cabanac M et al.. An attempt to clarify indications for hepatectomy for liver metastases from breast cancer.  Am J Surg. 2003;  185 158-164
• 6 Pentheroudakis G, Fountzilas G, Bafaloukos D et al.. Metastatic breast cancer with liver metastases: A registry analysis of clinicopathologic, management and outcome characteristics of 500 women.  Breast Cancer Res Treat. 2005;  97 237-244
• 7 Elias D, Lasser P H, Spielmann M et al.. Surgical and chemotherapeutic treatment of hepatic metastases from carcinoma of the breast.  Surg Gynecol Obstet. 1991;  172 461-464
• 8 Lawes D, Chopada A, Gillams A et al.. Radiofrequency ablation as a cytoreductive strategy for hepatic metastasis from breast cancer.  Ann R Coll Surg Engl. 2006;  88 639-642
• 9 Adam R, Aloia T, Krissat J et al.. Is liver resection justified for patents with hepatic metastases from breast cancer?.  Ann Surg. 2006;  244 897-908
• 10 Curley S A, Cusack Jr J C, Tanabe K K, Stoelzing O, Ellis L M. Advances in the treatment of liver tumors.  Curr Probl Surg. 2002;  39 449-571
• 11 Denys A L, De Baere T, Mahe C et al.. Radio-frequency tissue ablation of the liver: effects of vascular occlusion on lesion diameter and biliary and portal damages in a pig model.  Eur Radiol. 2001;  11(10) 2102-2108
• 12 Patterson E J, Scudamore C H, Owen D A et al.. Radiofrequency ablation of porcine liver in vivo: effects of blood flow and treatment time on lesion size.  Ann Surg. 1998;  227(4) 559-565
• 13 Yamasaki T, Kurokawa F, Shirahashi H et al.. Percutaneous radiofrequency ablation therapy for patients with hepatocellular carcinoma during occlusion of hepatic blood flow. Comparison with standard percutaneous radiofrequency ablation therapy.  Cancer. 2002;  95(11) 2353-2360
• 14 Elias D, Sideris L, Pocard M et al.. Intraductal cooling of the main bile ducts during radiofrequency ablation prevents biliary stenosis.  J Am Coll Surg. 2004;  198(5) 717-721
• 15 Stippel D L, Bangard C, Kasper H U et al.. Experimental bile duct protection by intraductal cooling during radiofrequency ablation.  Br J Surg. 2005;  92(7) 849-855
• 16 Livraghi T, Goldberg S N, Solbiati L et al.. Percutaneous radio-frequency ablation of liver metastases from breast cancer: initial experience in 24 patients.  Radiology. 2001;  220(1) 145-149
• 17 Sofocleous C T, Nascimento R G, Gonen M et al.. Radiofrequency ablation in the management of liver metastases from breast cancer.  AJR Am J Roentgenol. 2007;  189 883-889
• 18 Gunabushanam G, Sharma S, Thulkar S et al.. Radiofrequency ablation of liver metastases from breast cancer: results in 14 patients.  J Vasc Interv Radiol. 2007;  18 67-72
• 19 Pocard M, Pouillart P, Asselain B, Salmon R. Hepatic resection in metastatic breast cancer: results and prognostic factors.  Eur J Surg Oncol. 2000;  26 155-159
• 20 Livraghi T, Solbiati L, Meloni F, Ierace T, Goldberg S N, Gazelle G S. Percutaneous radiofrequency ablation of liver metastases in potential candidates for resection: the “test-of-time approach”.  Cancer. 2003;  97(12) 3027-3035
• 21 Dodd III G D, Frank M S, Aribandi M et al.. Radiofrequency thermal ablation: computer analysis of the size of the thermal injury created by overlapping ablations.  AJR Am J Roentgenol. 2001;  177 777-782
• 22 Solbiati L, Livraghi T, Goldberg S N et al.. Percutaneous radio-frequency ablation of hepatic metastases from colorectal cancer: long-term results in 117 patients.  Radiology. 2001;  221 159-166
• 23 Goldberg S N, Grassi C J, Cardella J F et al.. Image-guided tumor ablation: standardization of terminology and reporting criteria.  Radiology. 2005;  235 728-739
• 24 Livraghi T, Solbiati L, Meloni M F et al.. Treatment of focal liver tumors with percutaneous radio-frequency ablation: complications encountered in a multicenter study.  Radiology. 2003;  226(2) 441-451